SCHEMBL885498

SCHEMBL885498

CCOC(=O)c1[nH]c(=O)n(-c2ccccc2)c1-c1cccc(F)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAT2A P31153 1/20 0.49
MAPT P10636 5/20 0.45
ALDH1A1 P00352 4/20 0.45
GAA P10253 3/20 0.45
DRD2 P14416 1/20 0.45
DRD4 P21917 1/20 0.45
DRD3 P35462 1/20 0.45
THRB P10828 1/20 0.44
JAK2 O60674 1/20 0.44
JAK3 P52333 1/20 0.44
LMNA P02545 2/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
TRPM8 Q7Z2W7 1/20 0.43
NPC1 O15118 1/20 0.43
CYP1A2 P05177 1/20 0.43
HPGD P15428 1/20 0.43
XBP1 P17861 1/20 0.43
CYP2C19 P33261 1/20 0.43
POLB P06746 1/20 0.42
TDP1 Q9NUW8 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL885461 0.90 MAT2A (0.53) MAT2AMAPTALDH1A1GAALMNA
SCHEMBL885431 0.87 GABRA2 (0.52) MAT2AMAPTALDH1A1GAAJAK2
SCHEMBL885984 0.83 PIN1 (0.48) ALDH1A1LMNASMN1; SMN2CYP1A2HPGD
SCHEMBL885925 0.82 GABRA2 (0.50) MAT2AMAPTALDH1A1GAALMNA
SCHEMBL885747 0.80 NTRK1 (0.47) MAT2AMAPTALDH1A1GAATHRB
SCHEMBL3492563 0.80 MAT2A (0.44) MAT2AMAPTALDH1A1GAAALOX15
SCHEMBL885581 0.79 FAAH (0.47) MAT2AMAPTALDH1A1GAATHRB
SCHEMBL6208469 0.78 MAPT (0.56) MAT2AMAPTALDH1A1GAALMNA
SCHEMBL886152 0.77 MAT2A (0.48) MAT2AMAPTALDH1A1GAALMNA
SCHEMBL885677 0.77 ALDH1A1 (0.53) MAPTALDH1A1GAADRD2DRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008089005-A2 RENIN INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-07-24 WO claimed
US-8148367-B2 Renin inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-04-03 US disclosed
US-8148367-B2 Renin inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-04-03 US disclosed
US-8148367-B2 Renin inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-04-03 US disclosed
US-20100105665-A1 RENIN INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-04-29 US disclosed
US-20100105665-A1 RENIN INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-04-29 US disclosed
US-20100105665-A1 RENIN INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-04-29 US disclosed
WO-2008089005-A2 RENIN INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-07-24 WO disclosed
WO-2008089005-A2 RENIN INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-07-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100105665-A1 RENIN INHIBITORS REN, ACE, AGT MAT2A 2878/4885MAPT 2847/4885ALDH1A1 947/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.